ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates

分组1 - ChromaDex reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of 50% [1] - The company achieved revenues of $29.13 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 7.47%, and showing an increase from year-ago revenues of $21.2 million [2] - ChromaDex has outperformed the S&P 500, with shares adding about 3.7% since the beginning of the year, while the S&P 500 declined by 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.04 on revenues of $28.55 million, and for the current fiscal year, it is $0.12 on revenues of $120.8 million [7] - The Medical - Biomedical and Genetics industry, to which ChromaDex belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]